Summary of COVID-19 apilimod studies

1. Young et al., A Phase II Randomized, Double-Blind, Placebo-Controlled Study of LAM-002A for the Prevention of Progression of COVID-19

142 patient apilimod early treatment RCT: 199% higher mortality (p=1), 100% higher combined mortality/hospitalization (p=1), and 109% worse recovery (p=0.43).
RCT 142 COVID-19 patients showing no significant differences with apilimod treatment.
Apr 2021, NCT04446377, https://clinicaltrials.gov/study/NCT04446377, https://c19p.org/young3